Alkermes Plc (ALKS) Stake Lessened by Thornburg Investment Management Inc.

Share on StockTwits

Thornburg Investment Management Inc. reduced its position in shares of Alkermes Plc (NASDAQ:ALKS) by 7.6% during the 1st quarter, HoldingsChannel reports. The fund owned 1,133,566 shares of the company’s stock after selling 93,077 shares during the period. Thornburg Investment Management Inc.’s holdings in Alkermes were worth $41,364,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Nicollet Investment Management Inc. raised its position in shares of Alkermes by 2.1% during the 1st quarter. Nicollet Investment Management Inc. now owns 28,020 shares of the company’s stock worth $1,022,000 after purchasing an additional 565 shares during the last quarter. Nissay Asset Management Corp Japan ADV raised its position in shares of Alkermes by 4.7% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 13,531 shares of the company’s stock worth $494,000 after purchasing an additional 607 shares during the last quarter. CIBC Asset Management Inc raised its position in shares of Alkermes by 12.2% during the 1st quarter. CIBC Asset Management Inc now owns 8,382 shares of the company’s stock worth $306,000 after purchasing an additional 910 shares during the last quarter. Meeder Asset Management Inc. raised its position in shares of Alkermes by 155.3% during the 4th quarter. Meeder Asset Management Inc. now owns 1,810 shares of the company’s stock worth $53,000 after purchasing an additional 1,101 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. raised its position in shares of Alkermes by 2.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 114,873 shares of the company’s stock worth $3,390,000 after purchasing an additional 2,228 shares during the last quarter. 97.55% of the stock is currently owned by institutional investors and hedge funds.

Several research firms recently weighed in on ALKS. Zacks Investment Research upgraded shares of Alkermes from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a research report on Friday, March 22nd. BidaskClub downgraded shares of Alkermes from a “hold” rating to a “sell” rating in a research report on Tuesday. ValuEngine upgraded shares of Alkermes from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. TheStreet upgraded shares of Alkermes from a “d” rating to a “c-” rating in a research report on Tuesday, February 19th. Finally, Cantor Fitzgerald set a $33.00 price target on shares of Alkermes and gave the stock a “hold” rating in a research report on Wednesday, January 23rd. Six analysts have rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $40.50.

ALKS stock traded down $0.32 during mid-day trading on Friday, reaching $24.98. The company’s stock had a trading volume of 325,318 shares, compared to its average volume of 1,218,020. The company has a market cap of $3.98 billion, a price-to-earnings ratio of -356.86 and a beta of 1.72. The company has a current ratio of 2.94, a quick ratio of 2.65 and a debt-to-equity ratio of 0.25. Alkermes Plc has a fifty-two week low of $24.95 and a fifty-two week high of $51.70.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Thursday, April 25th. The company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.21. The company had revenue of $223.10 million during the quarter, compared to the consensus estimate of $218.84 million. Alkermes had a negative net margin of 15.86% and a negative return on equity of 2.08%. Alkermes’s quarterly revenue was down .9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.09) EPS. As a group, equities analysts forecast that Alkermes Plc will post -0.37 earnings per share for the current year.

In other news, Director Paul J. Mitchell sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $36.64, for a total transaction of $36,640.00. Following the completion of the sale, the director now owns 8,000 shares in the company, valued at approximately $293,120. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard F. Pops sold 60,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $33.32, for a total transaction of $1,999,200.00. Following the sale, the director now owns 760,604 shares of the company’s stock, valued at approximately $25,343,325.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 162,373 shares of company stock valued at $5,362,950. 4.71% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4344506/alkermes-plc-alks-stake-lessened-by-thornburg-investment-management-inc.html.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.

Featured Story: Fundamental Analysis

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks Investment Research Lowers Chesapeake Energy  to Sell
Zacks Investment Research Lowers Chesapeake Energy to Sell
Hingham Institution for Savings  Upgraded to “Buy” by BidaskClub
Hingham Institution for Savings Upgraded to “Buy” by BidaskClub
Hexcel Co.  Holdings Lessened by Fiduciary Trust Co.
Hexcel Co. Holdings Lessened by Fiduciary Trust Co.
Econ Financial Services Corp Takes Position in Archer Daniels Midland Co
Econ Financial Services Corp Takes Position in Archer Daniels Midland Co
Falcon Point Capital LLC Cuts Stake in ASGN Inc
Falcon Point Capital LLC Cuts Stake in ASGN Inc
Falcon Point Capital LLC Has $3.48 Million Position in BioTelemetry Inc
Falcon Point Capital LLC Has $3.48 Million Position in BioTelemetry Inc


© 2006-2019 Ticker Report